Drug Trial Radar · NCT03921424
Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
Last checked: Nov 19, 2026Latest source record: Jun 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
407
Actual
Start
Nov 5, 2019
Primary completion
May 3, 2021
Study completion May 3, 2021
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of V114 in children infected with HIV. Participants will be randomly assigned in a 1:1 ratio to receive either V114 or Prevnar 13™ followed 8 weeks later by a single dose of PNEUMOVAX™23. The primary objectives of this study are to evaluate the safety and tolerability of V114 in children 6 to 17 years of age inclusive infected with HIV and to evaluate the anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 30 days following vaccination with V114 or Prevnar 13™ by each vaccination group. There are no formal hypotheses.
Conditions
- Pneumococcal Infections
Interventions
V114Biological
15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
Prevnar 13™Biological
13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
PNEUMOVAX™23Biological
23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13™Time frame: Through 14 Days after Vaccination 1 (Up to Day 14)
- Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With V114 or Prevnar 13™Time frame: Through 14 Days after Vaccination 1 (Up to Day 14)
- Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) Following Vaccination 1 (V114 or Prevnar 13™) or Vaccination 2 (PNEUMOVAX™23) Through Completion of StudyTime frame: Through 6 Months after Vaccination 1 (Up to Day 194)
- Anti-PnPs Serotype-specific IgG Geometric Mean Concentrations (GMCs) at 30 Days Following Vaccination With V114 or Prevnar 13™Time frame: Day 30
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Perinatal HIV Research Unit ( Site 0042)
Johannesburg, Gauteng, South Africa
Wits Reproductive Health and HIV Institute (WRHI) ( Site 0043)
Johannesburg, Gauteng, South Africa
Family Clinic Research With UBUNTU ( Site 0045)
Cape Town, Western Cape, South Africa
Be Part Yoluntu Centre ( Site 0041)
Paarl, Western Cape, South Africa
CM Clinical Trial Unit-CM Clinical Trial Unit ( Site 0061)
Chiang Mai, Thailand
Chulalongkorn University-Pediatrics ( Site 0062)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital-Pediatric Infectious Diseases ( Site 0064)
Bangkok, Bangkok, Thailand
Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0063)
Amphoe Mueang, Changwat Khon Kaen, Thailand
Community Instit Dnipropetrovsk Municipal clinical Hospital #21 ( Site 0088)
Dnipro, Dnipropetrovsk Oblast, Ukraine
Dnipropetrovsk Regional Center of Socially Significant Diseases ( Site 0082)
Dnipro, Dnipropetrovsk Oblast, Ukraine
Odesa Regional Center of Socially Significant Diseases ( Site 0083)
Odesa, Odesa Oblast, Ukraine
Vinnitsa Reg Cntr for AIDS Prevention-Control-Outpatient clinic dept ( Site 0086)
Vinnytsia, Vinnytsia Oblast, Ukraine
Zaporizhzhya Regional Clinical Children's Hospital ( Site 0089)
Zaporizhzhya, Zaporizhzhia Oblast, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.